Abstract |
The Breast International Group (BIG) 1-98 study is a four-arm trial comparing 5 years of monotherapy with tamoxifen or with letrozole or with sequences of 2 years of one followed by 3 years of the other for postmenopausal women with endocrine-responsive early invasive breast cancer. From 1998 to 2003, BIG -98 enrolled 8,010 women. The enhanced design f the trial enabled two complementary analyses of efficacy and safety. Collection of tumor specimens further enabled treatment comparisons based on tumor biology. Reports of BIG 1-98 should be interpreted in relation to each individual patient as she weighs the costs and benefits of available treatments. Clinicaltrials.gov ID: NCT00004205.
|
Authors | Meredith M Regan, Karen N Price, Anita Giobbie-Hurder, Beat Thürlimann, Richard D Gelber, International Breast Cancer Study Group and BIG 1-98 Collaborative Group |
Journal | Breast cancer research : BCR
(Breast Cancer Res)
Vol. 13
Issue 3
Pg. 209
(May 26 2011)
ISSN: 1465-542X [Electronic] England |
PMID | 21635709
(Publication Type: Comparative Study, Journal Article, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't, Review)
|
Chemical References |
- Nitriles
- Receptors, Estrogen
- Receptors, Progesterone
- Triazoles
- Tamoxifen
- Letrozole
- ERBB2 protein, human
- Receptor, ErbB-2
|
Topics |
- Breast Neoplasms
(drug therapy)
- Chemotherapy, Adjuvant
- Clinical Trials, Phase III as Topic
- Double-Blind Method
- Female
- Humans
- Letrozole
- Nitriles
(administration & dosage, adverse effects, therapeutic use)
- Randomized Controlled Trials as Topic
- Receptor, ErbB-2
(metabolism)
- Receptors, Estrogen
(metabolism)
- Receptors, Progesterone
(metabolism)
- Tamoxifen
(administration & dosage, adverse effects, therapeutic use)
- Triazoles
(administration & dosage, adverse effects, therapeutic use)
|